2023-10-25 10:04:33 ET
A Connecticut-based %Biotech company is finding a ton of early success Wednesday morning after the company announced that an independent third-party review of the data from a site in its Tranquility II phase 3 trial showed “positive findings,” according to the release.
This news caused traders to be extremely optimistic on %BioXcelTherapeutics (Nasdaq: ) as shares opened up at $3.07/share (+31.20%) to kick things off on Wednesday. It should be an exciting session for this micro cap.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders.